The FDA has approved a genetically modified herpes virus that is injected directly into tumors as a treatment for advanced melanoma that has stopped responding to standard immunotherapy.
Tudriqev, given in combination with the immunotherapy nivolumab, received accelerated approval for adults with unresectable advanced cutaneous melanoma whose disease progressed on a PD-1 blocking antibody regimen. In the efficacy-evaluable group, 24.2% of patients responded, with responses lasting a median of 14.1 months.
